Dark

Check out our API

MYOV
Myovant Sciences Ltd.
stock NYSE

Inactive

Mar 9, 2023

26.98USD-0.037%(-0.01)2,256,078

Pre-market

0.00USD-100.000%(-26.99)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 27, 2022

09:52AM EST Myovant Sciences's Return on Invested Capital Insights Benzinga

Jan 26, 2022

08:00AM EST Enzyvant today announced the appointment of Johanna Rossell as Chief Commercial Officer. GlobeNewswire Inc

07:24AM EST Myovant Sciences: Q3 Earnings Insights Benzinga

06:57AM EST Myovant Sciences Q3 EPS $(0.68) Up From $(0.82) YoY, Sales $54.40M Benzinga

06:55AM EST Myovant Sciences Announces Financial Results for Third Quarter of GlobeNewswire Inc

03:59AM EST Earnings Scheduled For January 26, 2022 Benzinga

Jan 12, 2022

08:30AM EST Myovant Sciences to Host Third Fiscal Quarter 2021 Earnings GlobeNewswire Inc

Jan 10, 2022

06:59AM EST Myovant Sciences Sees Q3 Sales $54M-$55M Vs. $59.09M Est. Benzinga

06:55AM EST Myovant Sciences Announces Preliminary Financial Results for Third GlobeNewswire Inc

Jan 5, 2022

06:36AM EST SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $21 Benzinga

Jan 3, 2022

08:30AM EST Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Executive Officer of Myovant Sciences, Inc., will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 3:00 p.m. Eastern Time. GlobeNewswire Inc

Dec 10, 2021

10:27AM EST Sumitovant Biopharma Highlights Clinical, Regulatory And Commercial Achievements Across Portfolio Of Companies In Q2 2021 Benzinga

10:27AM EST Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial PR Newswire

Nov 23, 2021

08:43AM EST Myovant To Participate In Evercore ISI HealthCONx Conference Nov. 30 At 11:45 a.m. EST Benzinga

08:30AM EST Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021. David Marek, Chief Executive Officer of Myovant Sciences, Inc. will participate in a fireside chat at 11:45 a.m. Eastern Time. GlobeNewswire Inc

Nov 8, 2021

06:00AM EST Nancy Valente, M.D. Joins Myovant Sciences Board GlobeNewswire Inc

Oct 28, 2021

12:04PM EDT Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis PR Newswire

Oct 27, 2021

05:15AM EDT SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $23 Benzinga

Oct 26, 2021

10:35AM EDT Myovant Sciences Earnings Perspective: Return On Capital Employed Benzinga

08:36AM EDT The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children Benzinga

07:05AM EDT Myovant Sciences Q2 EPS $(0.23) Beats $(0.38) Estimate, Sales $77.90M Beat $71.40M Estimate Benzinga

06:55AM EDT Myovant Sciences Announces Financial Results for Second Quarter of GlobeNewswire Inc

04:39AM EDT Earnings Scheduled For October 26, 2021 Benzinga

Oct 19, 2021

07:05AM EDT Myovant Sciences And Pfizer Present Data On Relugolix Combination Therapy From Studies In Uterine Fibroids And Endometriosis At The American Society For Reproductive Medicine Congress Benzinga

06:58AM EDT Myovant Sciences and Pfizer Present Data on Relugolix Combination GlobeNewswire Inc

Oct 12, 2021

08:30AM EDT Myovant Sciences to Host Second Fiscal Quarter 2021 Earnings GlobeNewswire Inc

Oct 8, 2021

08:10PM EDT RETHYMIC is the first and only FDA-approved treatment indicated for immune reconstitution in pediatric patients with congenital athymia GlobeNewswire Inc

Sep 25, 2021

10:56AM EDT Notable Insider Buys Of The Past Week Include Designer Brands, MacroGenics And More Benzinga

Sep 13, 2021

07:37AM EDT Urovant Sciences Highlights Presentation Of Ambulatory Blood Pressure Data Showing That GEMTESA 75 mg In Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects On Blood Pressure Or Heart Rate Benzinga

Sep 9, 2021

11:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2021 Benzinga

08:57AM EDT Myovant Sciences (MYOV) and Pfizer Inc. (PFE) announced Thursday that the U.S. Food and Drug Administration accepted for review a supplemental New Drug Application or sNDA for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis. RTTNews

08:17AM EDT The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization Benzinga

07:46AM EDT Myovant, Pfizer: FDA Accepts To Review Myfembree SNDA For Pain Associated With Endometriosis RTTNews

06:59AM EDT Myovant Sciences And Pfizer Announce FDA Acceptance Of Supplemental New Drug Application For MYFEMBREE For The Management Of Moderate To Severe Pain Associated With Endometriosis Benzinga

06:58AM EDT -- Filing in endometriosis is supported by data from the Phase 3 SPIRIT program -- FDA PDUFA target action date is May 6, 2022 GlobeNewswire Inc

06:26AM EDT SVB Leerink Initiates Coverage On Myovant Sciences with Market Perform Rating, Announces Price Target of $24 Benzinga

Sep 4, 2021

11:45AM EDT The Past Week's Notable Insider Buys: Cano Health, Cricut, GoodRx, SelectQuote And More Benzinga

Sep 1, 2021

08:30AM EDT Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, will participate in the 2021 Baird Global Healthcare Conference on September 15, 2021. Company management will participate in a fireside chat at 2:35 p.m. Eastern Time in addition to participating in small group investor meetings. GlobeNewswire Inc

Aug 26, 2021

09:00AM EDT On average, pediatric congenital athymia patients spent 150.6 days each year in the hospital with a mean total cost of $5,534,121 for supportive care over three years GlobeNewswire Inc

Aug 23, 2021

08:13AM EDT 3 Stocks Insiders Are Buying Benzinga

Aug 21, 2021

02:07PM EDT The Past Week's Notable Insider Buys Included AppLovin, Cricut, Biotechs And More Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

04:22PM EDT Myovant Sciences Appoints Uneek Mehra as Chief Financial and Business Officer Benzinga

04:01PM EDT Myovant Sciences Appoints Uneek Mehra as Chief Financial and GlobeNewswire Inc

Aug 4, 2021

09:51AM EDT Myovant Highlights Results From Trials Of Enzyvant's RVT-802 Were Published In 'The Journal Of Allergy, Clinical Immunology' Benzinga

09:49AM EDT Kaplan-Meier estimated survival at one year and two years post treatment with investigational RVT-802 was 77% and 76%, respectively GlobeNewswire Inc

Jul 28, 2021

11:55AM EDT United Kingdom-based biotechnology company, Myovant Sciences Ltd. (MYOV) is down 10% on the Wednesday market after registering wider loss in the first quarter. The company also failed to meet the analyst estimates for earnings by a significant margin. RTTNews

07:36AM EDT Recap: Myovant Sciences Q1 Earnings Benzinga

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

06:57AM EDT Myovant Sciences Q1 EPS $(0.67) Misses $(0.33) Estimate, Sales $41.10M Miss $57.05M Estimate Benzinga

06:55AM EDT Myovant Sciences Announces Financial Results for First Quarter of GlobeNewswire Inc

04:27AM EDT Earnings Scheduled For July 28, 2021 Benzinga

Jul 27, 2021

11:13AM EDT Myovant Sciences's Earnings: A Preview Benzinga

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

06:39AM EDT Europe OK's Myovant's Relugolix Combo Therapy For Uterine Fibroids Benzinga

05:56AM EDT Myovant Sciences Announced European Commission Approval for RYEQO for the Treatment of Women With Uterine Fibroids Benzinga

02:46AM EDT The European Commission has approved Myovant Sciences' (MYOV) the marketing authorization application for RYEQO--relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg-- for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age, with no limitation for duration of use. RTTNews

02:14AM EDT Myovant Sciences: European Commission Approves Marketing Authorization Application For RYEQO RTTNews

02:00AM EDT Myovant Sciences Announces European Commission Approval for GlobeNewswire Inc

Jul 14, 2021

08:30AM EDT Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its first fiscal quarter 2021, ended June 30, 2021. The webcast and conference call will be held at8:30 a.m. Eastern Time / 5:30 a.m. Pacific TimeonJuly 28, 2021. GlobeNewswire Inc

Jul 7, 2021

06:54AM EDT Myovant Sciences Ltd On July 6 Submitted A SNDA To FDA For Once-Daily MYFEMBREE Benzinga

Jun 17, 2021

09:58AM EDT Myovant Sciences: Return On Capital Employed Insights Benzinga

Jun 2, 2021

09:52AM EDT Looking Into Myovant Sciences's Return On Capital Employed Benzinga

Jun 1, 2021

08:30AM EDT Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: GlobeNewswire Inc

May 27, 2021

08:24AM EDT The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs Benzinga

08:15AM EDT Myovant - Pfizer's Uterine Fibroids Treatment Wins FDA Approval Benzinga

07:50AM EDT Pfizer Inc. and Myovant Sciences announced that the U.S. Food and Drug Administration has approved Myfembree, the first once-daily treatment for heavy menstrual bleeding associated with uterine fibroids. RTTNews

May 26, 2021

04:18PM EDT Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids Benzinga

04:15PM EDT Myovant Sciences and Pfizer Receive FDA Approval for GlobeNewswire Inc

08:09AM EDT Myovant Sciences, Sumitovant Report Clinical, Corporate Milestones During Co.'s Q4 Benzinga

08:03AM EDT Sumitovant Biopharma Has a Strong Fourth Quarter with Significant Clinical PR Newswire

May 21, 2021

08:54AM EDT Myovant Sciences Receives Positive CHMP Opinion For RYEQO For Women With Uterine Fibroids RTTNews

08:31AM EDT Myovant Sciences Receives Positive CHMP Opinion For RYEQO For Treatment Of Women With Uterine Fibroids Benzinga

08:30AM EDT -- CHMP opinion recommending approval based on data from the Phase 3 LIBERTY program in women with uterine fibroids -- Gedeon Richter will commercialize RYEQO for uterine fibroids, if approved, in Europe -- Relugolix combination tablet for uterine fibroids is also under U.S. FDA review with a target action date of June 1, 2021 GlobeNewswire Inc

May 19, 2021

07:25AM EDT Myovant Sciences Announces On May 18th, The Co. Was Informed By The FDA That The Phase 3 SERENE Study Evaulating Relugolix Combination Tablet For The Prevention Of Pregnancy Has Been Placed On A Partial Clinical Hold Benzinga

06:51AM EDT Myovant Sciences Ltd. (MYOV) said the Food and Drug Administration has placed a partial clinical hold on the Phase 3 SERENE study of its relugolix combination tablet proposed for the prevention of pregnancy pending amendment of the study protocol to add bone mineral density monitoring. RTTNews

06:08AM EDT Myovant Sciences Says FDA Placed Partial Clinical Hold On Phase 3 SERENE Study MVT-601-050 RTTNews

May 11, 2021

12:47PM EDT Earnings Scheduled For May 11, 2021 Benzinga

11:03AM EDT Return On Capital Employed Overview: Myovant Sciences Benzinga

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

07:27AM EDT Myovant Sciences: Q4 Earnings Insights Benzinga

07:15AM EDT Myovant Q4 Loss/Shr $0.89 Vs Loss $0.73 Last Year RTTNews

06:58AM EDT Myovant Sciences Q4 EPS $(0.89) Beats $(0.99) Estimate, Sales $24.60M Miss $24.63M Estimate Benzinga

06:58AM EDT Myovant Sciences Announces Corporate Updates and Financial Results GlobeNewswire Inc

04:14AM EDT Earnings Scheduled For May 11, 2021 Benzinga

May 4, 2021

08:30AM EDT Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year GlobeNewswire Inc

Apr 12, 2021

07:55AM EDT Myovant Sciences (MYOV) and Pfizer Inc. (PFE) announced Monday that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) in healthy women ages 18-35 years who are at risk for pregnancy. RTTNews

07:02AM EDT Myovant, Pfizer: First Participant Dosed In Phase 3 SERENE Study RTTNews

06:58AM EDT Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet Benzinga

06:58AM EDT Myovant Sciences and Pfizer Announce First Participant Dosed in GlobeNewswire Inc

Apr 5, 2021

07:08AM EDT Myovant Sciences Appoints Lauren Merendino As Chief Commercial Officer RTTNews

Mar 29, 2021

06:59AM EDT Myovant Sciences Announces European Medicines Agency Has Validated Its Marketing Authorization Application For Relugolix for the Treatment of Advanced Prostate Cancer Benzinga

06:58AM EDT Myovant Sciences Announces European Medicines Agency Validation of GlobeNewswire Inc

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

08:23AM EDT Myovant/Pfizer's Relugolix Combo Therapy Shows Sustained Clinical Benefit In Uterine Fibroids Benzinga

06:51AM EDT Myovant & Pfizer: Long-term Study Supports Potential RTTNews

06:39AM EDT Myovant Sciences, Pfizer Announce Positive Data From Phase 3 LIBERTY Randomized Withdrawal Study RTTNews

06:32AM EDT Myovant Sciences And Pfizer Announce Phase 3 LIBERTY Randomized Withdrawal Study Of Once-Daily Relugolix Combination Therapy In Women With Uterine Fibroids Met PRimary Endpoint And All Three Key Secondary Endpoints Benzinga

06:30AM EDT Myovant Sciences and Pfizer Announce Positive Data from Phase 3 GlobeNewswire Inc

Mar 23, 2021

08:30AM EDT Myovant Sciences Announces Recipients of Forward GlobeNewswire Inc

Feb 22, 2021

08:30AM EST Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: GlobeNewswire Inc

Feb 18, 2021

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

Feb 17, 2021

05:05PM EST Pfizer And Myovant Sciences Announce The Publication of Their Phase 3 LIBERTY Studies Of Once Daily Relugolix Combination Therapy In Women With Uterine Fibroids In The New England Journal Of Medicine Benzinga

05:03PM EST Myovant Sciences and Pfizer Announce Publication in the New GlobeNewswire Inc

08:30AM EST Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 7 new employees with a grant date of February 16, 2021 pursuant to Myovants 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08. GlobeNewswire Inc

Feb 16, 2021

08:32AM EST -- Six women reflect on their period experiences and journeys to self-advocacy in new video series -- Video stories and additional information about Voices of Periods now available on femaleforwardtogether.com GlobeNewswire Inc

Feb 12, 2021

05:30AM EST SVB Leerink Maintains Market Perform on Myovant Sciences, Lowers Price Target to $26 Benzinga

Feb 11, 2021

06:55AM EST Myovant Sciences Announces Corporate Updates and Financial Results GlobeNewswire Inc

03:51AM EST Earnings Scheduled For February 11, 2021 Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Jan 29, 2021

08:30AM EST Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings GlobeNewswire Inc

Jan 26, 2021

05:28PM EST Myovant Sciences Says Sumitovant Biopharma Announces Positive One-Year Data From Co's Phase 3 SPIRIT Extension Study Of Once-Daily Relugolix Combination Therapy In Women With Endometriosis Benzinga

07:26AM EST Myovant Sciences (MYOV) and Pfizer Inc. (PFE) announced Tuesday positive one-year data from phase 3 SPIRIT extension study of once-daily Relugolix combination therapy in women with endometriosis. RTTNews

06:59AM EST Myovant, Pfizer Announce Positive One-Year Data From Phase 3 SPIRIT Extension Study RTTNews

06:57AM EST UPDATE: Myovant Sciences and Pfizer Announce '84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year' Benzinga

06:56AM EST Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis Benzinga

06:55AM EST Myovant Sciences and Pfizer Announce Positive One-Year Data from GlobeNewswire Inc

Jan 20, 2021

08:30AM EST Myovant Sciences Announces New Employment Inducement Grants Under GlobeNewswire Inc

Jan 8, 2021

10:04AM EST Benzinga's Top Upgrades, Downgrades For January 8, 2021 Benzinga

06:59AM EST SVB Leerink Downgrades Myovant Sciences to Market Perform, Lowers Price Target to $28 Benzinga

Jan 6, 2021

10:23AM EST Myovant Sciences shares were trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and announced a $30 price target. Benzinga

10:14AM EST Benzinga's Top Upgrades, Downgrades For January 6, 2021 Benzinga

07:14AM EST Goldman Sachs Downgrades Myovant Sciences to Neutral, Announces $30 Price Target Benzinga

Jan 5, 2021

02:57PM EST In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the release, the presentation time should be 2:50 p.m. Eastern Time, not 2:50 p.m. Pacific Time as previously stated. The corrected release follows: GlobeNewswire Inc

08:39AM EST The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data Benzinga

08:30AM EST Myovant Sciences(NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief executive officer of Myovant Sciences, Inc., will present at the virtual 39th AnnualJ.P. Morgan Healthcare ConferenceonTuesday, January 12, 2021 at 2:50 p.m. Pacific Time. GlobeNewswire Inc

06:58AM EST Myovant Sciences Announces US Availability Of ORGOVYX For Treatment Of Advanced Prostate Cancer Benzinga

06:58AM EST Myovant Sciences Announces U.S. Availability of GlobeNewswire Inc

Jan 4, 2021

07:00AM EST Myovant Appoints David Marek CEO RTTNews

06:58AM EST Myovant Sciences Appoints David Marek as CEO Benzinga

06:58AM EST Myovant Sciences(NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment ofDavid Marek as chief executive officer of Myovant Sciences, Inc. Mr. Marek will also serve as principal executive officer of Myovant Sciences Ltd. and as a member of its board of directors. Mr. Marek succeeds Lynn Seely, M.D. GlobeNewswire Inc

Jan 2, 2021

10:46AM EST Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 28, 2020

10:18AM EST Shares of Myovant Sciences Ltd. (MYOV) are gaining more than 28 percent or $6.44 in Monday's morning trade at $29.19, after hitting a new 52-week high of $30.90. RTTNews

06:45AM EST Myovant & Pfizer To Jointly Develop And Commercialize RTTNews

06:33AM EST Myovant Sciences, Pfizer Partner To Develop Relugolix In Oncology And Women's Health RTTNews

06:31AM EST UPDATE: Myovant To Receive Upfront Payment Of $650M In Addition To Potential Regulatory Milestones For Total Payment Up To $4.2B Benzinga

06:31AM EST Myovant Sciences Reports Collaboration With Pfizer To Develop, Commercialize Relugolix In Oncology, Women's Health Benzinga

06:30AM EST Myovant Sciences and Pfizer Announce Collaboration to Develop and GlobeNewswire Inc

Dec 18, 2020

04:52PM EST Myovant Sciences Announces FDA Approval Of ORGOVYX The First and Only Oral Gonadotropin-Releasing Hormone Receptor Antagonist For Advanced Prostate Cancer Benzinga

04:50PM EST -- ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO study -- Conference call and webcast to be held on December 21 at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time GlobeNewswire Inc

11:36AM EST Myovant Sciences Gets FDA Approval Of Orgovyx For The Treatment Of Advanced Prostate Cancer Benzinga

Dec 16, 2020

08:43AM EST Myovant Sciences Reports New Employment Inducement Grants Under NYSE Rule 303A.08 RTTNews

08:30AM EST Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity awards for 46 new employees with a grant date of December 15, 2020 pursuant to Myovants 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08. GlobeNewswire Inc

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 1, 2020

08:08AM EST The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit Benzinga

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 23, 2020

07:00AM EST Myovant Sciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men, invites investors and the general public to listen to webcasts at the following investor conferences: GlobeNewswire Inc

Nov 17, 2020

08:33AM EST Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 Benzinga

08:30AM EST MyovantSciences (NYSE:MYOV), a healthcare company focused on redefining care for women and for men,today announced that it approved equity awards for72new employees with a grant date ofNovember 15, 2020pursuant toMyovants2020 InducementPlan. The equity awards were granted totheemployees joining Myovant in accordance with NYSEs Listed Company Manual Rule 303A.08. GlobeNewswire Inc

Nov 12, 2020

10:18AM EST Myovant Sciences shares were trading lower after the company reported worse-than-expected Q2 EPS results. Benzinga

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

07:39AM EST Recap: Myovant Sciences Q2 Earnings Benzinga

07:11AM EST Myovant Sciences Q2 EPS $(0.75) Misses $(0.73) Estimate Benzinga

07:00AM EST Myovant Sciences Announces Corporate Updates and Financial Results GlobeNewswire Inc

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 2, 2020

08:30AM EST Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings GlobeNewswire Inc

Oct 21, 2020

08:33AM EDT Myovant Sciences Presents Additional Data On Relugolix Combination Therapy From Studies In Endometriosis And Uterine Fibroids Benzinga

08:30AM EDT Myovant Sciences Presents Additional Data on Relugolix Combination GlobeNewswire Inc

Oct 14, 2020

08:30AM EDT Myovant Sciences Appoints Ryan Crowe as Vice President, Investor GlobeNewswire Inc

Sep 30, 2020

08:20AM EDT Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Sept. 30, 2020: VLDR, CMPS, BYND, MYOV, AXTI Benzinga

Sep 29, 2020

03:06PM EDT Mid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares Plunge Benzinga

12:01PM EDT Mid-Day Market Update: Dow Tumbles Over 200 Points; Aptorum Group Shares Jump Benzinga

11:02AM EDT Why Myovant's Stock Is Trading Lower Today Benzinga

10:22AM EDT Mid-Morning Market Update: Markets Mostly Flat; McCormick Tops Q3 Views Benzinga

09:53AM EDT Shares of Myovant Sciences Ltd. (MYOV) are losing more than 24 percent or $5.15 in Tuesday's morning trade at $15.94. RTTNews

08:45AM EDT Myovant: Relugolix Did Not Achieve Statistical Superiority For Castration Resistance-free Survival RTTNews

08:35AM EDT Myovant Sciences Announces Relugolix Did Not Achieve Statistical Superiority For Castration Resistance-free Survival Compared To Leuprolide Acetate In Men With Metastatic Disease Through 48 Weeks Benzinga

08:30AM EDT Myovant Sciences Announces Results of Additional Secondary GlobeNewswire Inc

Sep 23, 2020

08:30AM EDT -- Prostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemic -- Myovant expands ongoing efforts to advance health equity with grant program to award up to $200,000 for innovative projects focused on improving access to healthcare GlobeNewswire Inc

Sep 14, 2020

08:32AM EDT Myovant Sciences Presents Additional Data On Bone Mineral Density In Women With Uterine Fibroids From Phase 3 LIBERTY Program And From Prospective Observational Study Benzinga

08:30AM EDT -- Relugolix combination therapy maintained bone mineral density through one year, consistent with bone mineral density changes observed in untreated women -- Findings presented at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting Virtual Event GlobeNewswire Inc

Aug 17, 2020

10:10AM EDT Shares of Myovant Sciences Ltd. (MYOV) are rising over 7% Monday morning, after the company announced that its New Drug Application or NDA for once-daily, oral relugolix combination tablet for the treatment of women with heavy menstrual bleeding associated with uterine fibroids has been accepted for review by the U.S. FDA. RTTNews

08:31AM EDT Myovant Sciences Announces FDA Acceptance Of New Drug Application For Once-Daily Relugolix Combination Tablet For Uterine Fibroids Benzinga

08:30AM EDT Myovant Sciences Announces FDA Acceptance of New Drug Application GlobeNewswire Inc

Aug 12, 2020

05:16AM EDT SVB Leerink Maintains Outperform on Myovant Sciences, Lowers Price Target to $28 Benzinga

Aug 11, 2020

08:33AM EDT Myovant Sciences Q1 EPS $(0.37) Up From $(0.89) YoY Benzinga

08:31AM EDT Myovant Sciences Announces Corporate Updates and Financial Results GlobeNewswire Inc

Aug 5, 2020

08:30AM EDT -- USD 200 million low-interest, five-year term loan commitment from Sumitomo Dainippon Pharma to further support planned commercialization of relugolix across multiple indications -- Agreement with Sunovion Pharmaceuticals provides access to well-established commercial infrastructure currently utilized across multiple successful products GlobeNewswire Inc

Share